Equine sarcoids are common therapy-resistant skin tumours induced by bovine papillomavirus type 1 or 2 (BPV1, BPV2) infection. We have previously shown that prophylactic vaccination with BPV1 L1 virus-like particles (VLPs) efficiently protects horses from experimental BPV1-induced pseudo-sarcoid development. Here, we assessed BPV1 L1 VLP vaccine-mediated long-term protection from experimental tumour formation in seven horses 5 years after immunization with three different doses of BPV1 L1 VLPs, and three unvaccinated control animals. Horses were challenged by intradermal inoculation with infectious BPV1 virions at 10 sites on the neck (10 6 virions per injection). In vaccinated horses, BPV1 challenge did not result in any apparent lesions irrespective of vaccine dosage and BPV1-neutralizing antibody titres that had dropped considerably over time and below the detection limit in one individual. Control horses developed pseudo-sarcoids at all inoculation sites. We conclude that immunization of horses with BPV1 L1 VLPs induces long-lasting protection against experimental BPV1 virion-induced disease.
Papillomaviruses (PVs) constitute a family of small, nonenveloped viruses consisting of an icosahedral capsid harbouring a circular double-stranded DNA genome of up to 8 kbp. Early research in natural animal hosts has revealed the pronounced species-specificity and tropism of PVs for epithelial keratinocytes. Delta-PVs (d-PVs) are an exception to this rule in that they can also infect dermal fibroblasts. In addition, some d-PVs, i.e. genetically highly homologous bovine PV types 1 and 2 (BPV1, BPV2) not only infect cattle but also a wide range of other ungulate species including antelopes, giraffes, water buffaloes and tapirs [1] [2] [3] [4] . Importantly, BPV1 and 2 are chiefly involved in the onset and maintenance of benign, yet locally aggressive, skin tumours in equids termed sarcoids [5] . Whilst sarcoids in Europe usually harbour BPV1, BPV2 is the predominant type infecting equids in western USA [6] . In addition, sarcoids collected in Brazil were shown to contain DNA of another d-PV, i.e. BPV type 13, that is genetically more than 90 % homologous to BPV1 and 2 [7] . A possible aetiological association of BPV13 with sarcoid development remains to be determined. BPV1/2 mainly reside in sarcoid fibroblasts as numerous viral episomes that multiply in synchrony with cell division. Accidental or iatrogenic trauma is a factor that contributes to disease onset and progression because wound healing in infected equids is achieved via proliferation of infected cells. Synchronous amplification of BPV1/2 episomes may entail oncogene expression to levels inducing cell transformation [5, 8] . Sarcoids affect up to 12 % of horses and other equids worldwide, are difficult to treat, and tend to recur in a more aggressive, multiple form following ineffective therapy or trauma. Therefore, sarcoids are still the most common dermatological reason for euthanasia, even though they do not metastasize [9] .
In an attempt to establish a vaccine for protection of horses and other equids from BPV1/2 infection-associated sarcoid development, we have previously generated BPV1 L1 viruslike particles (VLPs) [10] and evaluated their safety and immunogenicity in a dose-escalation trial involving 15 teaching horses at the Equine Clinic, University of Veterinary Medicine, Vienna, Austria, that were assigned to four groups. Groups 1-3 each comprised four horses that received 50, 100 or 150 µg of BPV1 L1 VLPs plus 250 mg Al (OH) 3 per dose as an adjuvant by deep intramuscular injection on days 0, 28 and 168 (May 2008). Group 4 consisted of three control horses that only received an alum adjuvant. Sera were collected immediately before and 2 weeks after each vaccination, and 1 year (June 2009) and 2 years (June 2010) after the final boost. BPV1-neutralizing antibody titres were determined from 1 : 2 serum dilution series (1 : 50-1 : 102 400) by BPV1 pseudovirion (PsV) neutralization assay [11] . Intramuscular BPV1 L1 VLP vaccination of horses proved safe and induced BPV1-neutralizing antibodies at levels correlating with protection in experimental animals and humans [11] . We then established a robust BPV1/ 2 horse challenge model [12] . Intradermal injection of horses with cow wart-derived BPV1 or BPV2 virions reliably induced nodular skin lesions that were morphologically and histologically indistinguishable from authentic sarcoids but regressed spontaneously, as first reported more than 50 years ago [13] [14] [15] . This model was used to address the potential of BPV1 L1 VLP vaccination to protect horses from experimental BPV1-induced formation of transient pseudo-sarcoids. Two immunizations of horses with 100 µg of BPV1 L1 VLP and 250 mg Al(OH) 3 4 weeks apart conferred complete protection from intradermal challenge with BPV1 virions 2 weeks after the boost and related pseudosarcoid development [16] .
In this study, we assessed the longevity of BPV1 L1 VLPinduced neutralizing antisera and immune-mediated protection of horses. To this aim, we collected blood from seven still-available BPV1 L1 VLP-immunized horses from the safety and immunogenicity trial in April 2013, i.e. almost 5 years after the third immunization (Table 1 ) [11] . Serum was used to determine individual BPV1-neutralizing antibody titres by BPV1 PsV neutralization assay [11] . Immediately after blood collection, these seven horses and three sarcoidfree control animals were inoculated with 10 6 cow wartderived BPV1 virions per intradermal injection at 10 sites on the neck as described previously [12, 16] . Subsequently, horses were monitored weekly for pseudo-sarcoid development.
Where applicable, tumour sizes were recorded using a calliper until pseudo-sarcoids had completely resolved. Heparinized blood (9 ml per horse) was taken on the day of virus challenge and then at weekly intervals for 11 weeks. PBMCs were isolated by routine Ficoll-Paque PLUS (GE Healthcare Life Sciences, Vienna, Austria) density gradient centrifugation and DNA extracted using a DNeasy Blood and Tissue Kit according to the manufacturer's instructions (Qiagen, Hilden, Germany). Presence of amplifiable PBMC DNA was confirmed by standard b-actin PCR. Then, 40 ng of PBMC DNA per 50 µl reaction mixture was subjected to BPV1 E5 PCR screening as described previously [12, 17] . Sarcoid DNA, PBMC DNA from a healthy horse and sterile water served as positive, negative and no template controls in this experiment. Amplification products (16 µl) were visualized by gel electrophoresis and ethidium bromide staining using a Quantitas 100 bp DNA ladder (Biozym, Vienna, Austria) as a molecular weight marker.
Sera were obtained once more 10 weeks after intradermal challenge from vaccinated and control horses (25 June 2013) . Then, BPV1 antibody titres were determined by PsV neutralization assay [11] to test whether inoculation had led to a booster effect in vaccinated horses and to a type-specific antibody response in control horses.
Importantly, seven of seven horses that had been immunized 5 years earlier with 50, 100 or 150 µg BPV1 L1 VLP were completely protected against pseudo-sarcoid disease induced by intradermal BPV1 inoculation. Protection was irrespective of the vaccine dosage and the individual BPV1-neutralizing antibody titres on the day of challenge (Table 2 ). BPV1-neutralizing antibody titres had dropped over time from levels 3200 in June 2008 to levels 400 on the day of intradermal challenge in April 2013. In one case (immunized horse no. 10), antibody titres decreased within a year from 12 800 (June 2008) to undetectable levels (Tables 1 and 2 ).
The three unvaccinated control horses tested negative for BPV1-neutralizing antibodies on the day of inoculation, as anticipated ( Table 2 , Fig. 1 ). They developed nodular pseudo-sarcoids at all inoculation sites, i.e. 10 lesions per horse. Maximum tumour sizes ranged between 6 (C2) and 8 mm (C1, C3) in diameter, and lesions spontaneously resolved within 3 (C1), 4 (C3) or 7 weeks (C2). Tumour sizes and growth kinetics matched those of previous BPV1 challenge trials [12, 16] .
Ten weeks post challenge (June 2013), BPV1-neutralizing antibody titres in six of seven vaccinated horses were two to eight times higher compared to titres from the challenge day. In the case of fully protected individual no. 10, however, antibody titres still remained below the detection limit (<50) ( Table 2 ). In one of three control horses, intradermal challenge with virion resulted in measurable seroconversion reflected by BPV1-neutralizing antibody titres amounting to 50 ( Table 2 ).
PBMC DNA extracted from heparinized blood collected at weekly intervals (weeks 1-11) was assessed for the presence of BPV1 E5 DNA by standard PCR [17] . E5 PCR scored positive for PBMC DNA of individual no. 8 corresponding to weeks 7, 8 and 9, and of control horse C3 corresponding to weeks 2 and 5-8 (data not shown). All other PBMC DNA isolates tested consistently negative throughout the experiment. Controls yielded anticipated results, thus testifying to the reliability of the assay.
The involvement of university teaching horses in a BPV1 L1 VLP safety and immunogenicity trial in 2007-2008 opened up the extraordinary opportunity to monitor seven of these horses in regard to the temporal course of vaccinationinduced BPV1-neutralizing antibody titres until 25 June 2013. Moreover, we were able to determine the long-term protective efficacy of three different doses of BPV1 L1 VLPs, as two to three horses per dosage group were still available for virus challenge (Tables 1 and 2 ).
In three of the seven horses that had received 50 (no. 4) or 100 µg VLP (nos 8 and 9), BPV1-neutralizing antibody titres increased during the first year after the third immunization,
i.e. in 2009, and then decreased considerably until the day of virus challenge in April 2013 (Tables 1 and 2 ). In three of the seven horses that had received 50 (no. 5) or 150 µg VLP (nos 12 and 14), BPV1-neutralizing antibody levels reached a maximum after the third immunization in 2008 and then dropped to low levels (200) until the day of virus challenge (Tables 1 and 2 ). The longevity of vaccination-induced protection of these six immunized horses from experimental BPV1-induced pseudo-sarcoid formation was probably mediated by low levels of BPV1-neutralizing antibodies still detectable in sera. The observed moderate increase of antibody titres in response to BPV1 challenge suggests that three immunizations of horses with BPV1 L1 VLPs in 2007-2008 might have elicited a specific memory B cell response. A robust secondary antibody response from memory B cells has been shown to occur in women immunized with high-risk HPV type L1 VLPs [18] [19] [20] . The comparatively weak increase of antibody titres observed in horses 10 weeks post challenge could be due to the intradermal route of virion administration. This interpretation is supported by the observation that the immune response of horses and cattle to natural BPV infection of the skin is compromised by passive immune escape [8] .
Individual no. 10 mounted a robust antibody response to three immunizations with 100 µg of BPV1 L1 VLP, as reflected by antibody titres of 12 800 4 weeks after the third immunization in 2008. These titres then irrevocably dropped below the detection level within the following year (Table 1) . Nonetheless, this horse showed complete protection from challenge-induced tumour formation (Table 2) . Since all horses were inoculated with the same batch of virions by the same person on two consecutive days [12, 16] , erroneous omission of inoculum as an explanation for this observation is very unlikely. Alternatively, protection may be based on a challenge-induced memory B cell response as observed in the other vaccinated individuals (Table 2) . Certainly, even the lowest dilution (1 : 50) of serum collected 10 weeks post challenge tested negative by BPV1 PsV neutralization assay. However, there is evidence that even low concentrations of anti-L1 antibodies can protect against high doses of infectious virions, as exemplarily shown in rabbits and dogs [21, 22] . In accordance with these early findings, more recent evidence suggests that antibody concentrations 100-fold below the detection limit of the PsV assay are still protective in mice [23] . In humans, HPV18-specific antibody titres induced by immunization with a quadrivalent HPV6/11/16/18 L1 VLP vaccine dropped below the detection level in about 40 % of vaccinees within 4 years. Yet, immunization still proved effective in protecting from HPV18 infection and induced disease [24] .
Immunization with HPV L1 VLPs was shown to elicit an antibody response that is 2-4 logs higher than the one induced by natural HPV infections [25] . In cattle, the antibody response to natural BPV infection is very poor [8] and, in sarcoid-affected equids, no anti-BPV1 antibodies are detectable from serum [26] . The high protective efficacy Fig. 1 . Unvaccinated control horses developed nodular pseudosarcoids at all inoculation sites as exemplarily shown (control horse C3). Two weeks after intradermal inoculation of unvaccinated control horse C3 with virion at 10 sites on the neck, three nodular pseudo-sarcoids became apparent, and seven lesions were already palpable at this point in time.
of PV L1 VLP-based vaccines is mainly based on circumvention of the viral epithelial defence line by intramuscular delivery and the ability of L1 VLPs to induce a strong T h cell-dependent B cell response. This response entails the generation of high titres of neutralizing antibodies and the establishment of B cell memory [27] .
Interestingly, several studies suggest that cytotoxic T lymphocyte (CTL) responses to L1 VLPs and effector memory T cells (CD8 + T EM ) likewise contribute to the prophylactic efficacy of L1 VLPs [28] . In 1998, De Bruijn et al. reported that a single injection of HPV16 L1 VLPs elicited efficient and type-specific CTL-mediated protection of C57Bl/6 mice from challenge with syngeneic HPV16-transformed C3 tumour cells that express L1, but not with L1-deficient TC1 tumour cells [29] . In more recent studies, immunization of healthy volunteers with HPV16 L1 VLPs was likewise shown to induce an L1-specific CTL response [30, 31] .
In analogy, three-time immunization of horses with BPV1 L1 VLPs in 2007-2008 may have elicited an L1-specific CTL and CD8 + T EM response. In a previous study, we have shown by immunohistochemistry that BPV1-induced pseudo-sarcoid cells express L1 protein [16] . Similarly, we detected L1 protein in naturally BPV1-induced equine sarcoids [32] . On these grounds, it is conceivable that BPV1 L1-specific CD8 + T EM may have contributed to the longevity of BPV1 L1-mediated protection of the study horses by migrating into the skin and becoming resident memory T cells supporting protection from intradermal challenge with BPV1 [28, 33] . This could also explain complete protection of individual no. 10 from virus challenge.
This hypothesis is also in agreement with the finding that vaccinia virus (VACV) skin infection leads to CD4 + T cell-and interferon g-independent recruitment of VACV-specific CTLs to the skin and the generation of long-lived resident CD8 + memory T cells (CD8 + T RM ) within the entire integument that protect efficiently from re-infection [28, 33] .
Taken together, BPV1 L1 VLP-mediated protection of seven horses from experimental BPV1-induced pseudo-sarcoid formation is shown to be long-lasting, irrespective of VLP dosage and individual BPV1-neutralizing antibody titres on the day of virus challenge. Therefore, we propose that longterm protection of BPV1 L1 VLP-immunized horses is provided by a sustained neutralizing antibody response aided by immune cell memory: plasma cells and memory B, but also memory T cells. Further in vivo studies are needed to test this intriguing possibility.
Protective efficacy of BPV1 L1 VLPs against challenge with wild-type virions and the demonstrated longevity of protection recommend this vaccine for routine use as sarcoid prophylaxis in horses and other equids. 
